TFS Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

TFS Capital’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-16,130	Closed	-$116K	–	833
2016 Q4	$116K	Buy	+16,130	New	+$177K	0.03%	619

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

TFS Capital's SNDX Position: Q1 2017 in Review

TFS Capital sold out of Syndax Pharmaceuticals (SNDX) in Q1 2017, closing a stake of 16,130 shares — an estimated $116K sold.

TFS Capital first reported a position in SNDX in Q4 2016 and held it in 1 quarter. The position peaked at $116K in Q4 2016. 63 funds tracked by Wall St. Rank hold SNDX as of Q1 2017.

TFS Capital reported no remaining Syndax Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
TFS Capital sold 16,130 Syndax Pharmaceuticals shares in Q1 2017, an estimated $116K.
TFS Capital first reported a position in Syndax Pharmaceuticals in Q4 2016 and held it in 1 quarter.
TFS Capital's Syndax Pharmaceuticals position peaked at $116K in Q4 2016.
63 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.